AI for Dry AMD

Book free trial to see how AI can detect Dry AMD and 70+ other pathologies/biomarkers

Book Intro

AI for Dry AMD (dAMD) on OCT detects the earliest pathological signs, such as drusen, pigmentary abnormalities, and other subclinical biomarkers of this pathology.

Altris AI, AI for OCT scan analysis, provides:

Rapid analysis with uncompromised accuracy: swift detection and localization of pathological changes.
An objective analysis of OCT: accurate volumetric and area measurements of all Dry AMD biomarkers.
Drusen measurements: type, volume, area, size.
Progression analysis: automated comparison of multiple examinations for quantitative monitoring of Dry AMD treatment.

Platform overview

Only practical features for eye care specialists and clinical research

GDPR compliant (all data is encrypted), CE-certified, and FDA- cleared (510k).

William C. Fruchtman, Optometry Owner

I was really excited to find Altris AI to bolster my skills identifying certain macular diseases. It's a great program and has guided me in the diagnosis of complex cases.

3 Oct, 2024

Scott Sedlacek Optometry Owner

Altris AI identified and described pathology that I could not. Early detection changes the treatment from doing nothing to something. Also, Altris AI described something that I thought was worse than it was. Saved me from over-referring. Patients love to see the color-coded images which help as an educational tool and get buy-in on the treatment plan which helps compliance.

1 Feb, 2024

Richard Clare Optometry Owner

We are adding a new OCT to one of our practices and may benefit from some extra support with AI to speed up the interpretation of results and assist the busy Optometry team.

Dec 7, 2023

Make informed decisions based on objective insights with AI OCT for dAMD.

Biomarker and pathology segmentation, analysis, and longitudinal monitoring.

Add OCT examinations from different visits: track pathological changes over time through quantitative analysis of Dry AMD biomarkers.

Detect: see all the biomarkers of Dry AMD with the help of color-coding.

Identify: explore DR biomarkers of your choice in terms of area and volume.

Track: how Dry AMD biomarkers transform over time to assess treatment effectiveness

How Altris AI works?

And what's the value of using Artificial intelligence for Dry AMD (dAMD)

Altris AI is a web platform created by retina experts for all eye care specialists and clinicians.
We’ve collected millions of OCT scans, and our team graphically labeled thousands of them to
create the Altris AI system that can:

Automatically prioritize scans based on the presence and extent of pathology.
Detect over 70 pathologies and signs, including early Dry AMD indicators like drusen, pigmentary abnormalities, unusual hyper or hyporeflectivity, and much more.
Measure and track pathological changes across multiple examinations.
Create customizable reports to enhance communication and facilitate informed decision-making for both you and your patients.

Formats

DICOM format will help you to extract maximum information. However, the system works with all
data formats, such as jpg, and png

OCT equipment

Altris AI is vendor-neutral. We work with all the OCT equipment producers

OCT reports

We create comprehensible OCT reports for patients and doctors

For clinical research

What you get with Altris AI:

Accelerate ophthalmic drug trial with AI.
Detect Dry AMD, nAMD, Geographic atrophy and their biomarkers ( +70 retinal pathologies and biomarkers) with AI.
Track the progression of biomarkers to assess drug efficiency.
Enroll the right patients based on fast biomarkers detection.
Reduce costs associated with manual scan review with automated analysis.

For eye care

We support you through the whole way

14 Days of Free Trial to see the value
Support during the whole trial period
Early glaucoma assessment module access
CE-certified, GDPR, HIPAA compliant, FDA clearance
Integration support with any EHR, EMR system.
Cloud data storage/on premises possible
Access to the whole functional during trial